drugset / Trial / NCT01128296
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
NaSingle-groupOpen-labelTreatment
Summary
The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe. The secondary goal is to determine if this new treatment regimen can effectively treat pancreatic cancer. This study will test the safety and efficacy of this combination in two parts, or phases.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-04
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1500 mg/m2 | Intravenous |
| Subject | Hydroxychloroquine | Small molecule | 200 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 400 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 800 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 1000 mg | Oral |
| Subject | Hydroxychloroquine | Small molecule | 1200 mg | Oral |